Drägerwerk stock: MWB keeps its EUR 135.00 target after Q3 figures

Published on 10/20/2026 at 15:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue rose 2.10 percent in 2026. Drägerwerk stock costs EUR 94.50 on October 20, 2026, down 1.36 percent versus the Xetra close.

Analyst target and Q3 figures

mwb research retained its Buy rating and EUR 135.00 target on October 15, 2026.
Third-quarter revenue rose 2.10 percent to EUR 851.00 million, while EBIT fell 15.00 percent to EUR 48.00 million.
Drägerwerk stock costs EUR 94.50 at Lang & Schwarz on October 20, 2026 at 3:04 p.m. CEST, 1.36 percent below the Xetra close of October 19, 2026.
The next earnings release is scheduled for October 28, 2026.

Pop-Art-Comic eines Rettungshelfers mit Gasmelder und Beatmungsmaske auf Halbton-Hintergrund — Drägerwerk AG & Co. KGaA Pop-Art Comic Rettungskraft Gasmelder Beatmungsmaske Sicherheitstechnik DE0005550636, Illustration mit AI erstellt.

mwb research retained its Buy rating and EUR 135.00 price target for Drägerwerk on October 15, 2026, after reviewing the preliminary third-quarter figures, according to ResearchHub. The target stands EUR 40.50 above the Lang & Schwarz price. Drägerwerk was trading at EUR 94.50 at Lang & Schwarz on October 20, 2026 at 3:04 p.m. CEST, down 1.36 percent versus the Xetra close of October 19, 2026 at EUR 95.80.

Q3 revenue grew 2.10 percent

Drägerwerk's preliminary third-quarter revenue increased 2.10 percent year over year to EUR 851.00 million. EBIT declined 15.00 percent to EUR 48.00 million, reducing the EBIT margin from 6.80 percent to 5.60 percent. The figures include EUR 20.10 million in customs-duty refunds, according to 4investors.

Safety orders reached EUR 926 million

Order intake provided a counterweight to the weaker operating result. Third-quarter orders rose 8.20 percent to EUR 926.00 million, led by Safety Technology, where currency-adjusted orders increased 20.20 percent to EUR 452.00 million. Medical Technology orders declined 3.00 percent, according to 4investors.

Valuation and reporting dates

Drägerwerk's full-year 2026 outlook calls for currency-adjusted revenue growth of 2.00 percent to 6.00 percent and an EBIT margin of 6.00 percent to 8.00 percent. The company also targets EUR 20.00 million to EUR 120.00 million in dividend-equivalent value, according to its Dräger investor-relations page.

The market capitalization stood at EUR 1.8 billion and the P/E ratio at 10.38 on October 20, 2026. The next earnings release is scheduled for October 28, 2026, while ResearchHub lists a Capital Markets Day for November 18, 2026.

Stock position and outlook

The 52-week range was EUR 66.00 to EUR 125.40 on October 20, 2026. The current price is 24.64 percent below the high, leaving the analyst target at EUR 135.00 above the market price. Drägerwerk's medical and safety technology businesses serve hospitals, emergency services, industry and public authorities.

Market position

Drägerwerk is listed on Xetra and belongs to the SDAX. Its valuation reflects the contrast between 8.20 percent order growth in the third quarter and a 15.00 percent decline in EBIT. The customs-duty refund also means the reported EUR 48.00 million EBIT figure includes a one-off effect.

Stock level after the Xetra close

Drägerwerk was trading at EUR 94.50 at Lang & Schwarz on October 20, 2026 at 3:04 p.m. CEST, 1.36 percent below the Xetra close of October 19, 2026 at EUR 95.80. The next scheduled company date is the October 28, 2026 earnings release. The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.